IC-MedTech Corporation   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2010
NCT01272830
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

IC-MedTech Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

vitamin k3 sodium bisulfite (synkavite) (1 trial)

Drugs in Phase 1 Trials (2)

benznidazole (Rochagan) (1 trial)

icm20 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Foreign Bodies (Phase 2)

Foreign-Body Reaction (Phase 2)

Osteolysis (Phase 2)

Synovitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3